Company Product Description Indication Status
Phase I
Innovent Biologics Inc., of Suzhou, China, and Hanmi Pharmaceutical Co. Ltd., of Beijing IBI-315 Recombinant bispecific antibody targeting PD-1 and HER2 HER2-expressing advanced solid malignancies First patient dosed; trial to determine safety, tolerability, initial efficacy and recommended phase II dose, either as monotherapy or in combination with chemotherapy
Seelos Therapeutics Inc., of New York SLS-002 Intranasal racemic ketamine Major depressive disorder Dosed first subjects in pharmacokinetic and pharmacodynamic study expected to enroll 62 healthy volunteers; preliminary data expected in first quarter of 2020
Phase III
Taiwan Liposome Co., of Taipei, Taiwan TLC-599 Non-opioid Bioseizer sustained-release version of dexamethasone sodium phosphate Osteoarthritis knee pain First patient enrolled in Excellence pivotal trial; study to test single and repeat dosing in about 500 patients; primary endpoint is magnitude of pain relief by WOMAC Pain score vs. placebo at weeks 16 and 40

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments